Arvinas (NASDAQ:ARVN) 株価情報

Arvinas

Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

Analyst Ratings

ARVN

過去3か月間に6人のアナリストがArvinas（NASDAQ:ARVN）に対してレーティングを発表し、好材料から悪材料まで幅広い視点を提供している。以下の表は、アナリストたちの最新のレーティングについて概要を簡単に示し、過去30日間とその前の日々とを比較して感情の変化を強調している。

アービナスに対する最新のアナリスト・レーティング

Arvinas Inc

<ul>
<li>AAPL</li>
<li>AMZN</li>
<li>TSLA</li>
<li>BULL</li>
<li>RDDT</li>
<li>GLD</li>
<li>MSTR</li>
<li>NVDA</li>
<li>DE</li>
<li>QQQ</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

Trading Ideas

AAPL

AMZN

BULL

MSTR

NVDA

RDDT

TSLA

Top 10 Trending Stocks On WallStreetBets As Of May 2, 2025 (Via Swaggy Stocks)

Evercore ISI Group analyst Steve Sakwa maintains Public Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSA#NYSE">PSA</a>) with a In-Line and raises the price target from $297 to $309.

News

Price Target

Evercore ISI Group Maintains In-Line on Public Storage, Raises Price Target to $309

WIIM

Cooper-Standard Holdings shares are trading higher after the company reported better-than-expected Q1 financial results.

FuboTV&nbsp;Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUBO#NYSE">FUBO</a>)&nbsp;reported&nbsp;earnings for the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45162938/fubos-global-streaming-business-exceeded-subscriber-guidance-achieved-revenue-targets-in-q1-2025" rel="noreferrer noopener">first-quarter&nbsp;of 2025</a> on Friday. The stock price declined after the results.
Revenue of the sports-first live TV streaming platform grew 8.1%&nbsp;year over year&nbsp;to $405.96 million, marginally missing the&nbsp;analyst&nbsp;consensus estimate of $415.45 million.
Adjusted EPS loss of 2 cents beat the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">analyst consensus estimate</a> of 9 cents.
Also Read: <a href="https://www.benzinga.com/news/earnings/25/02/44042301/fubotv-projects-subscriber-fall-in-q1-after-q4-topline-growth-stock-tumbles" target="_blank" rel="noreferrer noopener">FuboTV Projects Subscriber Fall In Q1 After Q4 Topline Growth, Stock Tumbles</a>
The company's adjusted EBITDA margin loss stood at .3% versus 9.9% Y/Y. 
North America Streaming:&nbsp;Revenue grew 3.5% Y/Y to $407.9 million, as paid subscribers declined 2.7% Y/Y to 1.47 million. Average revenue per user (ARPU) rose 1.0% Y/Y to $85.37.
Rest of the World Streaming: Revenue was $8.4 million, a 0.4% Y/Y decline, and paid subscribers declined 10.9% Y/Y to 354,000. ARPU grew by 10.9% Y/Y to $7.76.
As of March 31, FuboTV held $327.8 million in cash and equivalents. The company used $(61.99) million in free cash flow in the quarter, compared to $(71.30) million from a year ago.
Outlook:&nbsp;FuboTV expects second-quarter North American revenue of $340 million–$350 million and ROW revenue of $6.5 million-$7.5 million versus consensus of&nbsp;$387.68 million <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">analyst consensus estimate</a>.
Fubo expects 1.55 million-1.59 million total subscribers by the quarter.
It estimates North American subscribers to be 1.225 million-1.255 million, representing a 14% Y/Y decline at the midpoint.
It projects ROW 325,000-335,000 subscribers, representing a 17% Y/Y decline at the midpoint.
Price Action: Fubo stock traded lower by 7.51% at $2.71 premarket at last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/sports/25/04/44875151/fubo-extends-soccer-reign-in-canada-with-premier-league-renewal" target="_blank" rel="noreferrer noopener">Fubo Extends Soccer Reign In Canada With Premier League Renewal</a></li>
</ul>
Image: Logo courtesy of Fubo

Earnings

Guidance

FUBO

FuboTV Stock Drops After Q1 Subscriber Losses And Lower-Than-Expected Outlook

Cantor Fitzgerald analyst Deepak Mathivanan maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Overweight and raises the price target from $230 to $240.

Cantor Fitzgerald Maintains Overweight on Amazon.com, Raises Price Target to $240

<ul>
<li>It is estimated that by 2030 the prevalence of MASH (Metabolic Dysfunction-Associated Steatohepatitis) in the Canadian general population will increase from 5.2% to 6.5%.1&nbsp;</li>
<li>Left untreated, MASH can progress to serious and even fatal outcomes, such as cirrhosis, liver cancer, and the need for liver transplant.2&nbsp;</li>
</ul>
&nbsp;

Health Canada Accepts Semaglutide 2.4 mg As Supplemental New Drug Submission Under Priority Review Policy

Evercore ISI Group analyst Cory Kasimov maintains Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) with a In-Line and lowers the price target from $50 to $32.

MRNA

Evercore ISI Group Maintains In-Line on Moderna, Lowers Price Target to $32

TNMG

TNL Mediagene shares are trading lower after the company reported a year-over-year decrease in FY24 EPS results.

<a href="https://x.com/TvAlmasirah/status/1918290745770889474" title="https://x.com/TvAlmasirah/status/1918290745770889474">https://x.com/TvAlmasirah/status/1918290745770889474</a>

Macro Economic Events

Economics

iShares MSCI Israel Capped Investable Market Index Fund

Houthi-Linked Channel, Al Masirah TV, On X Shares Statement Regarding Military Operation Targeting Israeli In Haifa Area

Evercore ISI Group analyst Michael Binetti maintains Kohl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) with a In-Line and lowers the price target from $9 to $8.

Evercore ISI Group Maintains In-Line on Kohl's, Lowers Price Target to $8

AMWL

American Well shares are trading higher after the company reported better-than-expected Q1 financial results and issued Q2 sales guidance with its midpoint above estimates.

Citigroup analyst Samantha Semenkow initiates coverage on Structure Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPCR#NASDAQ">GPCR</a>) with a Buy rating and announces Price Target of $60.

Initiation

GPCR

Citigroup Initiates Coverage On Structure Therapeutics with Buy Rating, Announces Price Target of $60

Evercore ISI Group analyst John Dunn maintains Janus Henderson Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHG#NYSE">JHG</a>) with a In-Line and raises the price target from $33 to $35.

Janus Henderson Group plc Ordinary Shares

Evercore ISI Group Maintains In-Line on Janus Henderson Group, Raises Price Target to $35

AIRS

AirSculpt Technologies shares are trading higher after the company reported better-than-expected Q1 financial results and issued FY25 sales guidance with its midpoint above estimates.

Evercore ISI Group analyst Vijay Kumar maintains Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a In-Line and lowers the price target from $65 to $62.

HOLX

Evercore ISI Group Maintains In-Line on Hologic, Lowers Price Target to $62

PAPL

Pineapple Financial shares are trading lower after the company announced a $1.5 million public offering.

Evercore ISI Group analyst Duane Pfennigwerth maintains Hyatt Hotels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/H#NYSE">H</a>) with a Outperform and lowers the price target from $175 to $160.

Evercore ISI Group Maintains Outperform on Hyatt Hotels, Lowers Price Target to $160

Exact Sciences Corp.(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NYSE">EXAS</a>) on Thursday reported a first-quarter 2025 EPS loss of 21 cents, down from a 37-cent loss a year ago, beating the analyst&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus loss estimate of 38 cents.</a>
The company reported quarterly sales of $706.78 million, up 11% year over year on a reported and core revenue basis, beating the consensus&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45149849/exact-sciences-announces-first-quarter-2025-results" rel="noreferrer noopener">estimate of $688.64 million</a>.
Screening revenue was $540 million, an increase of 14%, and Precision Oncology's revenue was $166.8 million, an increase of 2%&nbsp;or 4% on a core revenue basis.
"Our strong first quarter results pave the way for 2025 to mark our most transformative year yet," said Kevin Conroy, chairman and CEO. &#8220;With growing momentum in our commercial organization and improved profitability, we raised our full-year outlook and continue to build a foundation for sustained long-term growth."
Guidance: Exact Sciences raised its fiscal 2025 sales guidance from $3.02 billion-3.08 billion to $3.07 billion-3.12 billion versus the consensus of $3.06 billion.
The guidance includes a screening sales forecast of $2.39 billion—$2.43 billion, compared to previous guidance of $2.35 billion—$2.39 billion.
Precision Oncology sales are expected to be $680 million—$695 million, compared to prior guidance of $675 million—$695 million.
The company expects 2025 Adjusted EBITDA of $425 million—$455 million, up from previous guidance of $410 million—$440 million.
&#8220;Simply put, this was a solid first quarter out of the gate and we believe Exact is well positioned to continue to show modest upside throughout the year. This upside, coupled with pipeline catalysts like blood-based CRC screening test data later this summer, keep us positive on the long-term prospects,&#8221; William Blair writes.
Analyst Andrew F. Brackmann added, &#8220;In sum, this was a positive update and helped build support for a bullish thesis that can drive the stock higher over the course of the year. Shares trade at a very compelling forward revenue multiple of 3.5 times, leaving ample room for multiple expansion.&#8221;
William Blair reiterated <a href="https://www.benzinga.com/quote/EXAS/analyst-ratings" target="_blank" rel="noreferrer noopener">the Outperform rating</a>.
Price Action: At the last check on Friday, EXAS stock was up 11.3% at $52.50 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45158118/analyst-cautions-on-snap-as-meta-and-google-benefit-from-ad-spending-shifts" target="_blank" rel="noreferrer noopener">Analyst Cautions On Snap As Meta And Google Benefit From Ad Spending Shifts</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Health Care

Movers

General

EXAS

Cancer Diagnostic Firm Exact Sciences' CEO Says Strong Q1 Paves Way For 'Transformative' 2025, Lifts Annual Guidance

TRUP

Trupanion shares are trading higher after the company reported better-than-expected Q1 financial results, issued Q2 sales guidance above estimates, and raised its FY25 sales guidance.

Evercore ISI Group analyst Peter Levine maintains Five9 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) with a Outperform and lowers the price target from $55 to $40.

FIVN

Evercore ISI Group Maintains Outperform on Five9, Lowers Price Target to $40

Press Releases

Arvinas to Participate in Upcoming Investor Conferences

Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial

Arvinas Announces Oral Presentation at 2025 International Conference on  Alzheimer's & Parkinson's Diseases

Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting

Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting

Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update

Legal

BREAKING: Block & Leviton Investigating Arvinas, Inc. (ARVN) For Securities Fraud After Shares Fall Over 20%; Investors Encouraged to Contact the Firm to Potentially Recover Losses

Comments

Arvinas

ニュース

パートナーシップ

ベンジンガ・グローバル